Surveillance studies of enhancing renal masses report on a mean @entity5 growth rate of about 0.3  cm/year. In most of these studies however, only small @entity5 in elderly @entity1 were followed. In the current report, we attempt to evaluate the growth rate of "clinically significant" @entity703 defined as @entity5 that were treated immediately upon diagnosis. 46 @entity1 (mean age 64  years SD 11  years) were treated for @entity703 . All had a cross-sectional imaging studies performed 6-60  months prior to diagnosis of @entity703 demonstrating no @entity5 . @entity5 growth rate was calculated by dividing @entity5 's largest diameter by the time interval between the normal kidney imaging and diagnosis of @entity703 . Mean @entity5 diameter was 4.5  cm (SD 2.4  cm). Mean time period from the normal imaging to diagnosis of @entity703 was 33.6  months (SD 18  months). According to the proposed model, the average growth rate of "clinically significant" @entity703 was 2.13  cm/year ( @entity15757 .45, range 0.2-6.5  cm/year). @entity5 growth rate correlated inversely with @entity1 's age (p  =  0.007). @entity1 gender or Fuhrman's grade did not correlate however. The growth rate of "clinically significant" @entity703 appears to be higher than the rate reported in surveillance trials. @entity703 tend to grow faster in young @entity1 . As such, variable growth rate should be taken into account when considering active surveillance in young @entity1 and when designing trials for evaluation of anti- @entity5 agents.

The growth rate of "clinically significant" XXXX .

@entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'Tumor', 'tumors'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Patient'] @entity15757 :: ('57306', 'Gene') :: ['SD 1'] @entity703 :: ('MESH:D007680', 'Disease') :: ['renal cancer', 'kidney cancer', 'renal carcinoma', 'renal carcinomas', 'Renal tumors']
@entity703 :: (MESH:D007680,Disease) :: ['renal cancer']
